Sacubitril intermediate and preparation method thereof

Through the aminotransferase-catalyzed transamination reaction and esterification reaction, the high cost and impurity problems of the synthesis route of Shakubaqu intermediate in the prior art were solved, and high purity and low cost preparation was achieved, the process flow was simplified, and the process was enhanced. Practicality and environmental friendliness of the method.

CN118931983AInactive Publication Date: 2024-11-12SUZHOU FLEMING BIOTECHNOLOGY CO LTD

Patent Information

Application Number
CN202410999883.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-24
Publication Date
2024-11-12
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing synthesis route of sacubatric intermediates uses expensive biphenylacetic acid and precious metals catalysis, and is high and complex, making it difficult to achieve industrial production, and the chemical selectivity is low, resulting in the production of isomer impurities, affecting the purity of the product. .

Method used

The aminotransferase catalyzed method is used to transfer compound B to produce compound C in a specific spatial configuration, and the sakubaquer intermediate is formed with ethanol through an esterification reaction, and the low price of ethanol and mild conditions of the esterification reaction are used. Reduces the impact on the spatial configuration of raw materials and the risk of impurities.

Benefits of technology

The chemical and optical purity of the Shakubaqu intermediate is improved, the production cost is reduced, the synthesis route is simplified, the practicality and environmental friendliness of the preparation method are enhanced, and the generation of by-products and impurity doping are avoided.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118931983A_ABST
    Figure CN118931983A_ABST
Patent Text Reader

Abstract

The invention relates to the field of chemical medicine synthesis, in particular to a sacubitril intermediate and a preparation method thereof. A compound B and an amino donor are subjected to an ammonia transfer reaction under catalysis of transaminase to generate a compound C, and carboxyl in the compound C reacts with ethanol to be esterified and converted into the sacubitril intermediate. The esterification reaction is easy to occur, and ethanol is low in price and easy to obtain, and is a better choice for synthesizing the sacubitril intermediate. Through transaminase catalyzed ammonia transfer reaction, a compound B with a specific steric configuration is converted into a compound C, so that generation of an isomer is inhibited, and the requirement on optical purity of the compound B is reduced. And the enzyme catalytic reaction also has the advantages of mild reaction conditions, high conversion rate and low possibility of side reaction, and is beneficial to improving the practicability of the preparation method. The sacubitril intermediate prepared through the preparation method has high chemical purity and optical purity, and preparation of a high-quality sacubitril product is facilitated.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of chemical drug synthesis, and in particular to a sacubitril intermediate and a preparation method thereof. Background Art

[0002] Sacubitril-valsartan is an angiotensin receptor neprilysin inhibitor commonly used for chronic heart failure and essential hypertension. It can inhibit the renin-angiotensin-aldosterone system by enhancing the blood pressure regulation of the natriuretic peptide system, thereby achieving multi-pathway blood pressure reduction and inhibiting target organ protection such as myocardial hypertrophy, myocardial fibrosis, and renal fibrosis. Sacubitril-valsartan is a single co-crystal composed of sacubitril and valsartan. During the preparation process, sacubitril and valsartan need to be generated separately and then co-crystallized, and when preparing sacubitril, its intermediates need to be synthesized first. The structural formula of a common sacubitril intermediate is as follows:

[0003]

[0004] At present, the paper Application of Transition-Metal Catalysis, Biocatalysis, and Flow Chemistry as State-of-the-Art Technologies in the Synthesis of LCZ696, J.Org.Chem.2020,85,11,6844-6853 discloses a synthetic route of the above-mentioned sacubitril intermediate:

[0005]

[0006] This route uses expensive felbinac as a starting material, and the preparation of chiral methylsuccinic acid monoester also requires expensive chiral ligands and precious metal catalysis, and consumes four equivalents of Grignard reagent. Therefore, the cost of this synthetic route is high, difficult to apply to industrial production, and has low practicality.

[0007] In addition, the following synthesis route of the above-mentioned sacubitril intermediate is also disclosed in U.S. Patent US2018362439A1:

[0008]

[0009] This route uses felbinac as a starting material, which is relatively expensive and the overall synthesis route is relatively complicated. Therefore, it is difficult to use it to achieve mass production of sacubitril and has low practicality.

[0010] In addition, Chinese patent CN112174798 also discloses two existing synthetic routes of the above-mentioned sacubitril intermediate.

[0011] Route 1 is shown below, where TA is ketotransaminase and KRED is ketoreductase.

[0012]

[0013] Route 2 is shown below, wherein TA is ketotransaminase.

[0014]

[0015] Although both routes can synthesize the above-mentioned sacubitril intermediate, the lactone raw material in route one is not widely available and is difficult to use for large-scale production, and the overall synthesis route is relatively cumbersome; the chemical selectivity of the addition of Grignard reagent and methylsuccinic anhydride in route two is not high, and products with specific spatial configurations cannot be obtained. Isomer impurities will be generated and doped in the product, so the practical value of these two synthesis routes is also low. Summary of the invention

[0016] The object of the present invention is to provide a method for preparing a sacubitril intermediate with high practicality.

[0017] In order to achieve the above object, the present invention provides the following technical solutions:

[0018] A method for preparing a sacubitril intermediate, comprising:

[0019] Obtaining compound B;

[0020] allowing the compound B to react with an amino donor under the catalysis of a transaminase to generate a compound C;

[0021] converting the compound C into the sacubitril intermediate by reacting the compound C with ethanol;

[0022] The chemical structures and synthetic routes of the above-mentioned compound B, compound C and sacubitril intermediate are as follows:

[0023]

[0024] Optionally, the compound B is obtained by reacting the compound D with the compound A, the compound A is derived from a Grignard reagent, and the structural formulas of the compound D and the compound A and the reaction formula for synthesizing the compound B are as follows:

[0025]

[0026] Wherein, M in the structural formula of the compound D is a monovalent metal ion, X in the structural formula of the compound A is a halogen, and THF is tetrahydrofuran.

[0027] Optionally, the step of reacting the compound D with the compound A to generate the compound B comprises:

[0028] Adding the compound D to tetrahydrofuran to obtain a first solution;

[0029] The temperature of the first solution is adjusted to a first temperature, and the Grignard reagent containing the compound A is added dropwise, and after the addition is completed, the temperature is adjusted to a second temperature, and reacted for a first time to obtain a first reaction solution;

[0030] An acidic quenching agent is added to the first reaction liquid for quenching, and the organic phase is extracted with a first extractant to obtain a first extract, and the first extract is dissolved in a first solvent and recrystallized at the first temperature to obtain the compound B.

[0031] Optionally, the first temperature is any value between -5°C and 5°C;

[0032] The second temperature is any value between 20°C and 40°C;

[0033] The first time is any value between 1h and 4h;

[0034] The acidic quencher is a hydrochloric acid solution with a concentration of any value between 1N and 3N;

[0035] The first extractant is isopropyl acetate;

[0036] The first solvent is a mixture of ethyl acetate and n-heptane;

[0037] The molar ratio of the added compound A to the added compound D is any value in the range of 1:(1 to 1.5).

[0038] Optionally, the compound B is obtained by reacting the compound D' and the compound A to obtain the compound E, and then reacting the compound E with trifluoroacetic acid, the compound A is derived from a Grignard reagent, and the structural formulas of the compound D', the compound A and the compound E and the reaction formula for synthesizing the compound B are as follows:

[0039]

[0040] Wherein, R in the structural formula of the compound D' is halogen or C(O)OR1, and R1 is C 1~6 Alkyl, X in the structural formula of the compound A is halogen.

[0041] Optionally, the step of generating the compound B after the compound D' and the compound A are reacted to obtain the compound E comprises:

[0042] Adding the compound D' to tetrahydrofuran to obtain a second solution;

[0043] The temperature of the second solution is adjusted to a third temperature, and the Grignard reagent containing the compound A is added dropwise, and after the addition is completed, the temperature is adjusted to a fourth temperature, and reacted for a second time to obtain a second reaction solution containing the compound E;

[0044] After the second reaction liquid undergoes a quenching reaction, the organic phase is extracted with a second extractant to obtain a second extract;

[0045] The trifluoroacetic acid is added to the second extract, and after reacting at the fifth temperature for a third time, the compound B is recrystallized.

[0046] Optionally, the third temperature is any value between -15°C and -5°C;

[0047] The fourth temperature is any value between -5°C and 10°C;

[0048] The fifth temperature is any value between 30°C and 50°C;

[0049] The second time is any value between 1h and 4h;

[0050] The third time is any value between 16h and 24h;

[0051] The second extracting agent is dichloromethane;

[0052] The molar ratio of the added compound D' to the added compound A is any value in the range of 1:(1 to 1.5).

[0053] Optionally, the step of reacting the compound B with an amino donor under the catalysis of a transaminase to generate the compound C comprises:

[0054] Add the compound B, the amino donor, the transaminase and the coenzyme to a triethanolamine buffer, adjust the pH value to any value between 8 and 8.5, and react at any value between 25° C. and 35° C. for any value between 20 h and 30 h to obtain a third solution;

[0055] Extracting the third solution with ethyl acetate, adjusting the pH value of the aqueous phase to any value between 4 and 5, and separating the precipitated solid compound C;

[0056] Wherein, the transaminase is EW-ATA-S124, the coenzyme is pyridoxal phosphate, and the amino donor is isopropylamine;

[0057] The mass of the transaminase is any value between 0.5% and 2% of the mass of the compound B;

[0058] The mass of the coenzyme is any value between 0.2% and 1% of the mass of the compound B;

[0059] The molar ratio of the isopropylamine to the compound B is any value between 4 and 6.

[0060] Optionally, the step of converting the compound C into the sacubitril intermediate by reacting the compound C with ethanol comprises:

[0061] Add the compound C to ethanol, add dichlorothionyl dropwise at a temperature between 40° C. and 60° C., and react for 4 h to 6 h after the addition is complete to obtain a fourth solution;

[0062] Concentrating the fourth solution and crystallizing at a temperature between -5°C and 5°C to obtain the sacubitril intermediate;

[0063] Wherein, the concentration of the compound C in the ethanol is any value between 0.55 mol / L and 5 mol / L;

[0064] The mass of the thionyl chloride is any value between 30% and 40% of the mass of the compound C.

[0065] In a second aspect, the present application also provides a sacubitril intermediate prepared by the above-mentioned preparation method.

[0066] According to a first aspect of the present invention, a compound B having a specific spatial configuration is subjected to a transamination reaction by a transaminase, thereby obtaining a compound C with a determined spatial configuration, and then an esterification reaction occurs between the carboxyl group in the compound C and ethanol, thereby generating a sacubitril intermediate with a determined spatial configuration. Since the esterification reaction conditions are mild, it is easy to occur, and it is not easy to affect the spatial configuration of the raw material reactant, and the other raw material reactant ethanol is cheap and easy to obtain, so the ester bond in the sacubitril intermediate formed by the esterification reaction has high practicality, which is a better choice for synthesizing the sacubitril intermediate. Since the transaminase-catalyzed transamination reaction has strong substrate specificity and chiral selectivity, the introduction of amino groups by enzyme catalysis helps to suppress the generation of isomers of compound C, and reduces the demand for the optical purity of compound B. Since it is not easy to generate by-products by synthesizing compound C by transaminase, it is convenient to separate the generated compound C from the reaction system to prevent a large amount of impurities from being doped in the system when the esterification reaction is carried out. In addition, the use of transaminase to catalyze the transamination reaction has the advantages of high conversion efficiency, mild reaction conditions, and little environmental pollution, which helps to improve the practicality of the preparation method.

[0067] According to the second aspect of the present invention, by improving the chemical selectivity in the reaction route, the obtained sacubitril intermediate has a higher chemical purity and optical purity, which is beneficial to improve the purity of the subsequently prepared sacubitril.

[0068] The above description is only an overview of the technical solution of the present invention. In order to more clearly understand the technical means of the present invention and implement it according to the contents of the specification, the following is a detailed description of the preferred embodiments of the present invention in conjunction with the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS

[0069] Figure 1 The present invention is a flowchart of the method for preparing the sacubitril intermediate shown in Example 1. DETAILED DESCRIPTION

[0070] The technical solution of the present invention will be described clearly and completely below in conjunction with the accompanying drawings. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0071] In the description of the present invention, it should be noted that the terms "center", "upper", "lower", "left", "right", "vertical", "horizontal", "inner", "outer", etc., indicating the orientation or positional relationship, are based on the orientation or positional relationship shown in the drawings, and are only for the convenience of describing the present invention and simplifying the description, rather than indicating or implying that the device or element referred to must have a specific orientation, be constructed and operated in a specific orientation, and therefore cannot be understood as limiting the present invention. In addition, the terms "first", "second", and "third" are used for descriptive purposes only, and cannot be understood as indicating or implying relative importance.

[0072] In the description of the present invention, it should be noted that, unless otherwise clearly specified and limited, the terms "installed", "connected", and "connected" should be understood in a broad sense, for example, it can be a fixed connection, a detachable connection, or an integral connection; it can be a mechanical connection or an electrical connection; it can be a direct connection, or it can be indirectly connected through an intermediate medium, or it can be the internal communication of two components. For ordinary technicians in this field, the specific meanings of the above terms in the present invention can be understood according to specific circumstances.

[0073] In addition, the technical features involved in the different embodiments of the present invention described below can be combined with each other as long as they do not conflict with each other.

[0074] See also Figure 1 The preparation method of the sacubitril intermediate protected by the present invention comprises:

[0075] S100. Obtain compound B.

[0076] S200, allowing compound B to react with an amino donor under the catalysis of transaminase to generate compound C.

[0077] S300, reacting compound C with ethanol to convert it into a sacubitril intermediate.

[0078] The chemical structures and synthetic routes of the above-mentioned compound B, compound C and sacubitril intermediate are as follows:

[0079]

[0080] Compound B with a specific spatial configuration is subjected to a transamination reaction by a transaminase, thereby obtaining a compound C with a determined spatial configuration, and then an esterification reaction occurs between the carboxyl group and ethanol in compound C, thereby generating a sacubitril intermediate with a determined spatial configuration. Since the esterification reaction conditions are mild, it is easy to occur, and it is not easy to affect the spatial configuration of the raw material reactant, and the other raw material reactant ethanol is cheap and easy to obtain, so the ester bond in the sacubitril intermediate formed by the esterification reaction has high practicality, which is a better choice for synthesizing sacubitril intermediates. Since the transaminase-catalyzed transamination reaction has strong substrate specificity and chiral selectivity, the introduction of amino groups by enzyme catalysis helps to suppress the generation of isomers of compound C, and reduces the demand for the optical purity of compound B. Since it is not easy to generate by-products by synthesizing compound C by transaminase, it is convenient to separate the generated compound C from the reaction system to prevent a large amount of impurities from being doped in the system when performing the esterification reaction. In addition, the use of transaminase-catalyzed transamination reaction also has the advantages of high conversion efficiency, mild reaction conditions, and low environmental pollution, which helps to improve the practicality of the preparation method.

[0081] In some embodiments, compound B is obtained by reacting compound D and compound A, compound A is derived from a Grignard reagent, and the structural formulas of compound D and compound A and the reaction formula for synthesizing compound B are as follows:

[0082]

[0083] Wherein, M in the structural formula of compound D is a monovalent metal ion, X in the structural formula of compound A is a halogen, and THF is tetrahydrofuran.

[0084] The Grignard reagent containing compound A can be obtained by reacting 4-halogenated methyl biphenyl and magnesium in a solvent, and 4-halogenated methyl biphenyl, such as 4-chloromethyl biphenyl, is a relatively low-priced biphenyl derivative and is also a relatively commonly used biphenyl derivative in the field of chemical drug synthesis. The Grignard reagent containing compound A and the compound D with a certain spatial configuration, i.e., the organic salt of 2-cyanopropionic acid, undergo nucleophilic addition reaction to generate compound B, which helps to obtain compound B with a certain spatial configuration, and the reaction route is relatively simple. Compound D can be directly obtained by reacting (R)-2-methyl-4-cyanopropionic acid with metal ions, and (R)-2-methyl-4-cyanopropionic acid is relatively easy to obtain and can be prepared by an asymmetric synthesis method, so that the synthetic route in the present invention has high practicality.

[0085] In some embodiments, the steps of reacting compound D with compound A to generate compound B include:

[0086] S110, adding compound D to tetrahydrofuran to obtain a first solution.

[0087] S120, adjusting the temperature of the first solution to a first temperature, and dropwise adding a Grignard reagent containing compound A, and after the dropwise addition is completed, adjusting the temperature to a second temperature, and reacting for a first time to obtain a first reaction solution.

[0088] S130, adding an acidic quenching agent to the first reaction liquid for quenching, extracting the organic phase with a first extractant to obtain a first extract, dissolving the first extract in a first solvent and recrystallizing at a first temperature to obtain compound B.

[0089] Tetrahydrofuran is used as a solvent to prevent oxidation caused by water and oxygen during the reaction. Excessive compound D is consumed by an acidic quencher to reduce the risk of generating by-products, which helps to improve the purity of compound B.

[0090] In some embodiments, the first extractant is isopropyl acetate.

[0091] The first temperature is any value between -5°C and 5°C, for example, any value among -5°C, -3°C, -1°C, 1°C, 3°C and 5°C.

[0092] The second temperature is any value between 20°C and 40°C, for example, may be any value between 20°C, 25°C, 30°C, 35°C and 40°C.

[0093] The first time is any value between 1 hour and 4 hours, for example, it can be any value between 1 hour, 2 hours, 3 hours and 4 hours.

[0094] The acidic quencher is a hydrochloric acid solution with a concentration of any value between 1N and 3N. The concentration of the hydrochloric acid solution can be, for example, any value among 1N, 1.5N, 2.5N and 3N.

[0095] The first solvent is a mixture of ethyl acetate and n-heptane, wherein the ratio of ethyl acetate to n-heptane is any one of (1:1.5), (1:1) and (1.5:1).

[0096] The molar ratio of the added compound A to compound D is any value in the range of 1:(1 to 1.5), for example, any value in the range of (1:1), (1:1.1), (1:1.2), (1:1.3), (1:1.4) and (1:1.5), which helps to promote the full reaction of compound A and reduce costs.

[0097] In some embodiments, compound B is obtained by reacting compound D' and compound A to obtain compound E, and then reacting compound E with trifluoroacetic acid. Compound A is derived from a Grignard reagent. The structural formulas of compound D', compound A and compound E and the reaction formula for synthesizing compound B are as follows:

[0098]

[0099] Wherein, R in the structural formula of compound D' is halogen or C(O)OR1, and R1 is C 1~6 Alkyl, X in the structural formula of compound A is halogen.

[0100] The Grignard reagent including compound A can be obtained by the reaction of 4-halogenated methylbiphenyl, and compound D' can be prepared by the reaction of (R)-2-methylsuccinic acid mono-tert-butyl ester, which is low in cost and easy to obtain, thus helping to improve the practicability of the preparation method.

[0101] In some embodiments, the steps of reacting compound D' with compound A to obtain compound E and then generating compound B include:

[0102] S140, adding compound D' to tetrahydrofuran to obtain a second solution.

[0103] S150, adjusting the temperature of the second solution to a third temperature, and dropwise adding a Grignard reagent containing compound A. After the dropwise addition is completed, adjusting the temperature to a fourth temperature, and reacting for a second time to obtain a second reaction solution containing compound E.

[0104] S160, after the second reaction solution undergoes quenching reaction, the organic phase is extracted with a second extractant to obtain a second extract.

[0105] S170, adding trifluoroacetic acid to the second extract, reacting at the fifth temperature for a third time, and then recrystallizing to obtain compound B.

[0106] In some embodiments, the second extractant is dichloromethane.

[0107] The third temperature is any value between -15°C and -5°C, for example, it may be any value among -15°C, -13°C, -11°C, -9°C, -7°C and -5°C.

[0108] The fourth temperature is any value between -5°C and 10°C, for example, it may be any value among -5°C, -3°C, -1°C, 1°C, 3°C, 5°C, 8°C and 10°C.

[0109] The fifth temperature is any value between 30°C and 50°C, for example, may be any value among 30°C, 35°C, 40°C, 45°C and 50°C.

[0110] The second time is any value between 1 hour and 4 hours, for example, it can be any value between 1 hour, 2 hours, 3 hours and 4 hours.

[0111] The third time is any value between 16 hours and 24 hours, for example, it can be any value between 16 hours, 18 hours, 20 hours, 22 hours and 24 hours.

[0112] The molar ratio of the added compound D' to the compound A is any value in the range of 1:(1 to 1.5), for example, any value in the range of (1:1), (1:1.1), (1:1.2), (1:1.3), (1:1.4) and (1:1.5), which helps to promote the full reaction of the compound A and reduce the cost.

[0113] In some embodiments, reacting compound B with an amino donor under the catalysis of a transaminase to generate compound C comprises:

[0114] S210. Add compound B, an amino donor, a transaminase and a coenzyme into a triethanolamine buffer, adjust the pH value to any value between 8 and 8.5, for example, any value between 8, 8.1, 8.2, 8.3, 8.4 and 8.5, and react at any value between 25°C and 35°C, for example, any value between 25°C, 27°C, 29°C, 31°C, 33°C and 35°C for 20h to 30h, for example, any value between 16h, 18h, 20h, 22h and 24h, to obtain a third solution.

[0115] S220, extracting the third solution with ethyl acetate, adjusting the pH value of the aqueous phase to any value between 4 and 5, for example, any value between 4, 4.2, 4.4, 4.6, 4.8 and 5, and separating the precipitated solid compound C.

[0116] Among them, the transaminase is EW-ATA-S124, the coenzyme is pyridoxal phosphate, and the amino donor is isopropylamine;

[0117] The mass of the transaminase may be any value in the range of 0.5% to 2% of the mass of the compound B, for example, any value in the range of 0.5%, 0.8%, 1%, 1.3%, 1.5% and 2%.

[0118] The mass of the coenzyme may be any value in the range of 0.2% to 1% of the mass of the compound B, for example, any value in the range of 0.2%, 0.4%, 0.6%, 0.8% and 1%.

[0119] The molar ratio of isopropylamine to compound B may be any value in the range of 4 to 6, for example, any value in the range of 4, 4.5, 5, 5.5 and 6.

[0120] In some embodiments, reacting Compound C with ethanol to convert it into a sacubitril intermediate comprises:

[0121] S310. Add compound C to ethanol, and add dichlorothionyl dropwise at a temperature of 40°C to 60°C, for example, 40°C, 45°C, 50°C, 55°C and 60°C. After the addition is completed, react for 4h to 6h, for example, 4h, 4.5h, 5h, 5.5h and 6h to obtain a fourth solution.

[0122] S320, concentrating the fourth solution and crystallizing it at any temperature between -5°C and 5°C, for example, any temperature between -5°C, -3°C, -1°C, 1°C, 3°C and 5°C, to obtain a sacubitril intermediate.

[0123] The concentration of compound C in ethanol is any value between 0.55 mol / L and 5 mol / L, for example, any value between 0.55 mol / L, 0.9 mol / L, 1.5 mol / L, 2 mol / L, 3 mol / L and 5 mol / L.

[0124] The mass of thionyl chloride may be any value between 30% and 40% of the mass of compound C, for example, any value among 30%, 32%, 34%, 36%, 38% and 40%.

[0125] Please refer to the following examples for details.

[0126] Embodiment 1:

[0127] See also Figure 1 The method for preparing the sacubitril intermediate shown in a preferred embodiment of the present application comprises the following steps:

[0128] S100. Obtain compound B.

[0129] S200, allowing compound B to undergo transamination reaction with an amino donor to generate compound C.

[0130] S300, converting compound C into a sacubitril intermediate by reacting compound C with ethanol.

[0131] Among them, the chemical structures of compound B, compound C and sacubitril intermediate are as follows:

[0132]

[0133] In this embodiment, step S100 includes:

[0134] S110, adding 13.5 g, i.e., 130 mmol, of compound D into 60 ml of tetrahydrofuran to obtain a first solution.

[0135] S111, add 3.12g, i.e. 130mmol, of magnesium flakes and 3.7g of 4-chloromethylbiphenyl to 60ml of tetrahydrofuran, stir thoroughly, add 1 grain of iodine, heat to 40°C in a water bath, the reaction is initiated rapidly, then continue to drop 4-chloromethylbiphenyl-tetrahydrofuran solution at a low temperature, react at 40°C-50°C for 1 hour after the dropwise addition, separate the supernatant, and obtain a Grignard reagent. The 4-chloromethylbiphenyl-tetrahydrofuran solution is obtained by dissolving 18.5g of 4-chloromethylbiphenyl in 40ml of tetrahydrofuran, and 4-chloromethylbiphenyl reacts with magnesium in tetrahydrofuran to generate compound A.

[0136] S120, place the first solution in a water bath at 0°C, and slowly drop the Grignard reagent into the first solution, stop the water bath after the dropwise addition is complete, allow the system temperature to gradually rise to room temperature, and continue the reaction for 2 hours to obtain a first reaction solution. At this time, the room temperature is 25°C, and the ratio of the molar amount of compound A in the Grignard reagent to the molar amount of compound D in the first solution is approximately (1:1.2).

[0137] S130, add 150 ml of 2N hydrochloric acid solution to the first reaction solution for quenching, extract the organic phase with 200 ml of isopropyl acetate, and wash the extracted organic phase with 60 ml of saturated sodium chloride solution to obtain a first extract. The first extract is dissolved in a mixture of ethyl acetate and n-heptane configured in a ratio of 1:1, cooled to 0°C for recrystallization, and the crystallized solid is separated by filtration and dried to obtain compound B. 24 g of compound B is recovered in this step, and the yield is about 85%.

[0138] The structural formulas of compound A, compound B and compound D, and the reaction formula of the reaction occurring in the above step S120 are as follows:

[0139]

[0140] 4-Chloromethylbiphenyl is a relatively cheap and easily available biphenyl derivative. Using 4-chloromethylbiphenyl as the biphenyl group donor of the sacubitril intermediate helps to improve the overall practicality of the reaction route and preparation method.

[0141] In this example, compound D was obtained by self-synthesis, and 4-chloromethylbiphenyl and other reagents were purchased. The synthesis method of compound D includes:

[0142] S101. Add 80 ml of dichloromethane, 10.4 g, i.e. 100 mmol, of methyl D-lactate, 12.3 g, i.e. 120 mmol, of triethylamine and 22 g, i.e. 115 mmol, of p-toluenesulfonyl chloride into a reaction flask, place in a water bath and maintain the temperature between 30°C and 35°C. After reacting for 5 hours, add 50 ml of distilled water to wash the organic layer, separate the organic layer, add anhydrous sodium sulfate to the separated organic layer, dry it, filter out the desiccant, concentrate it, add 50 ml of tetrahydrofuran to dilute it, and obtain a tetrahydrofuran solution of sulfonylated lactate.

[0143] S102, in another reaction bottle, add 80ml of tetrahydrofuran, 10.9g, i.e. 110mmol of methyl cyanoacetate and 3.8g, i.e. 110mmol of 60% sodium hydride, add dropwise the sulfonylated lactate tetrahydrofuran solution obtained in step S101 at a temperature of 35°C, after the addition is complete, heat to 50°C and continue to react for 3 hours, concentrate under reduced pressure to remove about half of the solvent, add 80ml of toluene and 60ml of 4N sodium hydroxide solution, react at room temperature for 2 hours, add dropwise hydrochloric acid to neutralize to any value of pH 1 to 2, in this embodiment, the pH value is 1.4, heat and reflux for 1 hour, cool to room temperature, take the organic layer and concentrate, add 60ml of a toluene-methanol mixture mixed in a ratio of 1:1 to dissolve the residue, add dropwise 19g of 28% sodium methoxide solution at a temperature of 50°C, gradually precipitate solid sodium salt, cool to room temperature, filter and dry the solid sodium salt, and obtain 9.1g of compound D in total, with a calculated yield of 67%.

[0144] The synthetic routes in step S101 and step S102 are as follows:

[0145]

[0146] The compound D obtained by D-methyl lactate has a certain spatial configuration, which helps to make the spatial configuration of the final sacubitril intermediate consistent with the demand. D-methyl lactate and other reactants are both low-priced and easy to obtain. The overall synthesis route is easy to operate and does not involve harsh reaction conditions, and has high practicality.

[0147] In this embodiment, step S200 includes:

[0148] S210, add 30 ml of triethanolamine buffer solution to the reaction bottle, and the pH value of the triethanolamine buffer solution is 8.3, continue to add 6 ml of dimethyl sulfoxide, 3 g of isopropylamine, i.e. 50 mmol of amino donor and 2.82 g, i.e. 10 mmol of compound B obtained in step S130, continue to add 25 mg of transaminase EW-ATA-S124 and 14 mg of coenzyme pyridoxal phosphate, react at 30°C for 24 hours to obtain a third solution.

[0149] S220. Extract the third solution with 30 ml of ethyl acetate. After removing the organic layer, add hydrochloric acid dropwise to the aqueous layer to neutralize to a pH value of 4 to 5. In this embodiment, the pH value is adjusted to 4.7. At this time, solid matter precipitates in the solution. The solid matter is filtered and washed with water. After vacuum drying, 2.43 g of compound C is obtained. The calculated yield is 86%.

[0150] The structural formulas of compound B and compound C, and the reaction formula of the reaction occurring in the above step S220 are as follows:

[0151]

[0152] The transamination reaction achieved by transaminase has strong chemical selectivity, which helps to obtain compound C with a specific spatial configuration, and then obtain a sacubitril intermediate with a specific spatial configuration.

[0153] In this embodiment, step S300 includes:

[0154] S310, add 150 ml of anhydrous ethanol and 28.3 g of compound C into a reaction bottle, and then drop 10 g of (SOCl2) at room temperature. After the dropwise addition, heat to 50°C and react for 5 hours to obtain a fourth solution.

[0155] S320, after removing ethanol from the fourth solution by concentrating under reduced pressure, 80 ml of methyl tert-butyl ether was added and the solution was cooled to 0°C. At this time, solid crystals gradually appeared in the liquid. After filtering and drying, 32.35 g of sacubitril intermediate was obtained, and the calculated yield was 93%.

[0156] The purity of the sacubitril intermediate obtained by high performance liquid chromatography was 98%, and the optical purity (ee%) of the sacubitril intermediate obtained by polarimeter was 98%.

[0157] Embodiment 2:

[0158] The difference between this embodiment and the first embodiment is that, in this embodiment, step S100 includes:

[0159] S140, adding 80 ml of tetrahydrofuran and 27.7 g of compound D' into a reaction bottle to obtain a second solution, wherein the molar amount of compound D' is 100 mmol.

[0160] S141, preparing another portion of Grignard reagent in the same manner as step S111 in Example 1.

[0161] S150, cooling the second solution to -10°C, and adding dropwise the Grignard reagent obtained in step S141. After the addition is completed, placing the reaction flask in an ice-water bath for 2 hours to obtain a second reaction solution containing compound E.

[0162] S160, adding 150 ml of 2N hydrochloric acid solution to the second reaction liquid to quench the reaction, adding 200 ml of dichloromethane for extraction, separating the organic layer, adding 50 ml of distilled water for washing, separating the organic layer again to obtain a second extract.

[0163] S170. Add 60 ml of trifluoroacetic acid to the second extract, react at 40°C for 20 hours, evaporate the solvent, add a 1:1 ethyl acetate-n-heptane mixture to the residue, cool to 0°C for recrystallization, filter and dry to obtain 22.2 g of compound B, with a calculated yield of 78%.

[0164] The structural formulas of the compound D' in this embodiment, the compound A in the Grignard reagent, the generated compound E and the compound B, and the reaction formulas of the reactions occurring in the above-mentioned step S150 and step S160 are as follows:

[0165]

[0166] In this embodiment, compound D' was obtained by self-synthesis, and 4-chloromethylbiphenyl and other reagents were purchased. The synthesis method of compound D' includes:

[0167] S103, add 800ml tetrahydrofuran, 145g dimethyl malonate, 38g 60% sodium hydride into the reaction bottle, and add 166g (R)-2-chloropropionic acid tert-butyl ester dropwise at 35°C. The molar amounts of dimethyl malonate and sodium hydride are both 1.1mol, and the molar amount of (R)-2-chloropropionic acid tert-butyl ester is 1mol. After the dropwise addition is completed, continue the reaction at 50°C for 3 hours, concentrate under reduced pressure to remove the solvent, add 500ml toluene and 600ml 4N sodium hydroxide solution, react at room temperature for 2h, and add hydrochloric acid dropwise to neutralize to any value between 1 and 2, which is 1.3 in this embodiment. After heating and refluxing for 1h, cool to room temperature, take the organic layer for concentration, add petroleum ether, filter and dry the precipitated solid, and obtain 141g (R)-2-methylsuccinic acid monotert-butyl ester, with a calculated yield of 75%. The reaction formula in this step is as follows:

[0168]

[0169] S104, add 100ml of methanol and 37.6g of (R)-2-methylsuccinic acid mono-tert-butyl ester obtained in step S103 to another reaction bottle, and add 38.5g of 28% sodium methoxide solution at room temperature. The molar amount of (R)-2-methylsuccinic acid mono-tert-butyl ester and sodium methoxide is 200mmol. After the addition is complete, reduce the pressure and concentrate to dryness, continue to add 120ml of tetrahydrofuran, stir and disperse the sodium salt to form a suspension, at 35°C, add 24g, i.e. 200mmol of tert-butyryl chloride, continue to react for 2h after the addition is complete, filter and separate the filtrate and filter cake, wherein the filter cake contains sodium chloride impurities, wash the filter cake with 50ml of tetrahydrofuran and collect the washing liquid, combine the washing liquid with the filtrate, and concentrate to obtain the compound D' required in step S140. The reaction formula in this step is as follows:

[0170]

[0171] The amount of each substance used in step S200 of this embodiment is 10 times the amount of each substance used in step S200 of embodiment 1, including 100 mmol of compound B obtained in step S170, totaling 28.2 g. In this embodiment, a total of 25.1 g of compound C is obtained, and the calculated yield is 89%.

[0172] The amount of each substance used and the operation method in step S300 of this embodiment are the same as those in Example 1, and a total of 33 g of sacubitril intermediate is obtained in this embodiment, and the calculated yield is 95%. The purity of the sacubitril intermediate obtained by high performance liquid chromatography is 98%, and the optical purity (ee%) of the sacubitril intermediate obtained by polarimeter is 97%.

[0173] Embodiment three:

[0174] The difference between this embodiment and the second embodiment is only that the structure and preparation method of compound D' are different.

[0175] The synthesis method of compound D' in this embodiment includes step S103, and further includes:

[0176] S105, add 80 ml of cyclohexane, 37.6 g of (R)-2-methylsuccinic acid mono-tert-butyl ester obtained in step S103 and 0.2 g of dimethylformamide to the reaction bottle, heat to 50°C, add 26 g, i.e. 220 mmol, of thionyl chloride, and after the addition is complete, place in a water bath at 55°C and react for 2 h, concentrate under reduced pressure to remove the cyclohexane solvent, add 50 ml of cyclohexane again, and concentrate again to obtain the residue 2-methylsuccinic acid mono-tert-butyl ester chloride, i.e. compound D' in this embodiment. The reaction formula in this step is as follows:

[0177]

[0178] In step S100 of this embodiment, 100 mmol of compound D' is also added, and its mass is 27.7 g. 22.8 g of compound B is obtained, and the calculated yield is 80%. The structural formula of compound D' and the reaction formula involved in step S100 of this embodiment are as follows:

[0179]

[0180] The dosage of each substance and the operation method in step S200 and step S300 of this embodiment are the same as those in Example 2. In this embodiment, a total of 33.21 g of sacubitril intermediate was obtained, and the calculated yield was 96%. The purity of the sacubitril intermediate obtained by high performance liquid chromatography was 98%, and the optical purity (ee%) of the sacubitril intermediate obtained by polarimeter was 97%.

[0181] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0182] The above-mentioned embodiments only express several implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.

Claims

1. A method for preparing a sacubitril intermediate, characterized in that: include: Obtaining compound B; allowing the compound B to react with an amino donor under the catalysis of a transaminase to generate a compound C; converting the compound C into the sacubitril intermediate by reacting the compound C with ethanol; The chemical structures and synthetic routes of the above-mentioned compound B, compound C and sacubitril intermediate are as follows:

2. The preparation method according to claim 1, characterized in that The compound B is obtained by reacting the compound D and the compound A, wherein the compound A is derived from a Grignard reagent, and the structural formulas of the compound D and the compound A and the reaction formula for synthesizing the compound B are as follows: Wherein, M in the structural formula of the compound D is a monovalent metal ion, X in the structural formula of the compound A is a halogen, and THF is tetrahydrofuran.

3. The preparation method according to claim 2, characterized in that: The operation steps of reacting the compound D with the compound A to generate the compound B include: Adding the compound D to tetrahydrofuran to obtain a first solution; The temperature of the first solution is adjusted to a first temperature, and the Grignard reagent containing the compound A is added dropwise, and after the addition is completed, the temperature is adjusted to a second temperature, and reacted for a first time to obtain a first reaction solution; An acidic quenching agent is added to the first reaction liquid for quenching, and the organic phase is extracted with a first extractant to obtain a first extract, and the first extract is dissolved in a first solvent and recrystallized at the first temperature to obtain the compound B.

4. The preparation method according to claim 3, characterized in that: The first temperature is any value between -5°C and 5°C; The second temperature is any value between 20°C and 40°C; The first time is any value between 1h and 4h; The acidic quencher is a hydrochloric acid solution with a concentration of any value between 1N and 3N; The first extractant is isopropyl acetate; The first solvent is a mixture of ethyl acetate and n-heptane; The molar ratio of the added compound A to the added compound D is any value in the range of 1:(1 to 1.5).

5. The preparation method according to claim 1, characterized in that: The compound B is obtained by reacting the compound D' with the compound A to obtain the compound E, and then reacting the compound E with trifluoroacetic acid. The compound A is derived from a Grignard reagent. The structural formulas of the compound D', the compound A and the compound E and the reaction formula for synthesizing the compound B are as follows: Wherein, R in the structural formula of the compound D' is halogen or C(O)OR1, and R1 is C 1~6 Alkyl, X in the structural formula of the compound A is halogen.

6. The preparation method according to claim 5, characterized in that: The operation steps of generating the compound B after the compound D' and the compound A react to obtain the compound E include: Adding the compound D' to tetrahydrofuran to obtain a second solution; The temperature of the second solution is adjusted to a third temperature, and the Grignard reagent containing the compound A is added dropwise, and after the addition is completed, the temperature is adjusted to a fourth temperature, and reacted for a second time to obtain a second reaction solution containing the compound E; After the second reaction liquid undergoes a quenching reaction, the organic phase is extracted with a second extractant to obtain a second extract; The trifluoroacetic acid is added to the second extract, and after reacting at the fifth temperature for a third time, the compound B is recrystallized.

7. The preparation method according to claim 6, characterized in that: The third temperature is any value between -15°C and -5°C; The fourth temperature is any value between -5°C and 10°C; The fifth temperature is any value between 30°C and 50°C; The second time is any value between 1h and 4h; The third time is any value between 16h and 24h; The second extracting agent is dichloromethane; The molar ratio of the added compound D' to the added compound A is any value in the range of 1:(1 to 1.5).

8. The preparation method according to any one of claims 1 to 7, characterized in that: The step of reacting the compound B with an amino donor under the catalysis of a transaminase to generate the compound C comprises: Add the compound B, the amino donor, the transaminase and the coenzyme to a triethanolamine buffer, adjust the pH value to any value between 8 and 8.5, and react at any value between 25° C. and 35° C. for any value between 20 h and 30 h to obtain a third solution; Extracting the third solution with ethyl acetate, adjusting the pH value of the aqueous phase to any value between 4 and 5, and separating the precipitated solid compound C; Wherein, the transaminase is EW-ATA-S124, the coenzyme is pyridoxal phosphate, and the amino donor is isopropylamine; The mass of the transaminase is any value between 0.5% and 2% of the mass of the compound B; The mass of the coenzyme is any value between 0.2% and 1% of the mass of the compound B; The molar ratio of the isopropylamine to the compound B is any value between 4 and 6.

9. The preparation method according to any one of claims 1 to 7, characterized in that: The step of reacting the compound C with ethanol to convert it into the sacubitril intermediate comprises: Add the compound C to ethanol and drop thionyl chloride, and after the dropwise addition, react at a temperature of 40° C. to 60° C. for 4 h to 6 h to obtain a fourth solution; Concentrating the fourth solution and crystallizing at a temperature between -5°C and 5°C to obtain the sacubitril intermediate; Wherein, the concentration of the compound C in the ethanol is any value between 0.55 mol / L and 5 mol / L; The mass of the thionyl chloride is any value between 30% and 40% of the mass of the compound C.

10. A sacubitril intermediate, characterized in that The invention is prepared by the preparation method according to any one of claims 1 to 9.

Citation Information

Patent Citations

  • Sacubitril intermediate and preparation method of sacubitril intermediate and sacubitril

    CN105924355A

  • Sacubitril intermediate and preparation method thereof

    CN106977415A

  • Synthesis method of sacubitril valsartan sodium LCZ696

    CN112174798A

  • Transaminase mutant as well as coding gene and application thereof

    CN115772509A

  • Preparation method of sacubitril key intermediate

    CN117756622A

Cited By

  • Preparation method of sacubitril intermediate

    CN119841759A